CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Freeze-Dried Black Raspberry Powderdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03140280
NCT03140280Phase 2Completed
CompareCT.gov

A Pilot Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)

Ehab L Atallah·interventional·Posted May 4, 2017·Updated Nov 4, 2022

In Brief

A Phase 2 clinical trial evaluating Freeze-Dried Black Raspberry Powder for Myelodysplastic Syndromes. Completed, enrolled 23 participants across 1 site.

Detailed Summary

This is a phase II, single-group pilot study to evaluate efficacy and methylation. This study's overarching aim is to evaluate the systemic effects of black raspberries in patients with myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm. Twenty-one patients with MDS will be treated with 25 gm (2x/day) of BRB powder taken orally.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 4, 2017
Enrollment StartJun 5, 2017
Primary CompletionJun 1, 2019
Study CompletionMay 28, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.2 years ago

Interventions

Freeze-Dried Black Raspberry Powderdrug

25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.